These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 21889330)

  • 1. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma.
    Tomita Y; Uemura H; Fujimoto H; Kanayama HO; Shinohara N; Nakazawa H; Imai K; Umeyama Y; Ozono S; Naito S; Akaza H;
    Eur J Cancer; 2011 Nov; 47(17):2592-602. PubMed ID: 21889330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
    Rini BI; Wilding G; Hudes G; Stadler WM; Kim S; Tarazi J; Rosbrook B; Trask PC; Wood L; Dutcher JP
    J Clin Oncol; 2009 Sep; 27(27):4462-8. PubMed ID: 19652060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma.
    Fruehauf J; Lutzky J; McDermott D; Brown CK; Meric JB; Rosbrook B; Shalinsky DR; Liau KF; Niethammer AG; Kim S; Rixe O
    Clin Cancer Res; 2011 Dec; 17(23):7462-9. PubMed ID: 21976544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
    Rini BI; Escudier B; Tomczak P; Kaprin A; Szczylik C; Hutson TE; Michaelson MD; Gorbunova VA; Gore ME; Rusakov IG; Negrier S; Ou YC; Castellano D; Lim HY; Uemura H; Tarazi J; Cella D; Chen C; Rosbrook B; Kim S; Motzer RJ
    Lancet; 2011 Dec; 378(9807):1931-9. PubMed ID: 22056247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
    Schiller JH; Larson T; Ou SH; Limentani S; Sandler A; Vokes E; Kim S; Liau K; Bycott P; Olszanski AJ; von Pawel J
    J Clin Oncol; 2009 Aug; 27(23):3836-41. PubMed ID: 19597027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
    Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
    Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Axitinib in the treatment of metastatic renal cell carcinoma.
    Ho TH; Jonasch E
    Future Oncol; 2011 Nov; 7(11):1247-53. PubMed ID: 22044199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.
    Mancuso A; Di Paola ED; Leone A; Catalano A; Calabrò F; Cerbone L; Zivi A; Messina C; Alonso S; Vigna L; Caristo R; Sternberg CN
    BJU Int; 2012 Jan; 109(2):200-6. PubMed ID: 22212284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
    Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI
    Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma.
    Eto M; Uemura H; Tomita Y; Kanayama H; Shinohara N; Kamei Y; Fujii Y; Umeyama Y; Ozono S; Naito S; Akaza H;
    Cancer Sci; 2014 Dec; 105(12):1576-83. PubMed ID: 25283266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Axitinib for the management of metastatic renal cell carcinoma.
    Escudier B; Gore M
    Drugs R D; 2011; 11(2):113-26. PubMed ID: 21679004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-related quality of life during treatment for renal cell carcinoma: results from a phase II study of axitinib.
    Trask PC; Bushmakin AG; Cappelleri JC; Bycott P; Liau K; Kim S
    Acta Oncol; 2008; 47(5):843-51. PubMed ID: 18568482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study.
    Rixe O; Bukowski RM; Michaelson MD; Wilding G; Hudes GR; Bolte O; Motzer RJ; Bycott P; Liau KF; Freddo J; Trask PC; Kim S; Rini BI
    Lancet Oncol; 2007 Nov; 8(11):975-84. PubMed ID: 17959415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study.
    Calvo E; Escudier B; Motzer RJ; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Ravaud A; Kim D; Panneerselvam A; Anak O; Figlin RA
    Eur J Cancer; 2012 Feb; 48(3):333-9. PubMed ID: 22209391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma.
    Naito S; Tsukamoto T; Murai M; Fukino K; Akaza H
    BJU Int; 2011 Dec; 108(11):1813-9. PubMed ID: 21481133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study.
    Johnson AC; Matias M; Boyle H; Escudier B; Molinier A; Laguerre B; Helissey C; Brachet PE; Dugué AE; Mourey L; Coquan E; Joly F
    BMC Cancer; 2017 May; 17(1):355. PubMed ID: 28532444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.
    McNamara MG; Le LW; Horgan AM; Aspinall A; Burak KW; Dhani N; Chen E; Sinaei M; Lo G; Kim TK; Rogalla P; Bathe OF; Knox JJ
    Cancer; 2015 May; 121(10):1620-7. PubMed ID: 25565269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Axitinib-induced proteinuria and efficacy in patients with metastatic renal cell carcinoma.
    Nozawa M; Sugimoto K; Ohzeki T; Minami T; Shimizu N; Adomi S; Saito Y; Nose K; Yoshimura K; Uemura H
    Int J Clin Oncol; 2016 Aug; 21(4):748-755. PubMed ID: 26694813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-significant impact of proteinuria on renal function in Japanese patients with metastatic renal cell carcinoma treated with axitinib.
    Miyake H; Harada K; Imai S; Miyazaki A; Fujisawa M
    Int J Clin Oncol; 2015 Aug; 20(4):796-801. PubMed ID: 25424248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma.
    Zakharia Y; Zakharia K; Rixe O
    Expert Opin Drug Discov; 2015; 10(8):925-35. PubMed ID: 26039031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.